Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 55,812 shares, a decline of 44.5% from the December 31st total of 100,600 shares. Based on an average daily volume of 1,063,819 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 1,063,819 shares, the short-interest ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Down 0.2%

BAYRY stock opened at $13.15 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The company’s 50-day moving average price is $11.02 and its 200 day moving average price is $9.06. Bayer Aktiengesellschaft has a 52 week low of $5.30 and a 52 week high of $13.98. The company has a market cap of $51.75 billion, a P/E ratio of -146.09, a P/E/G ratio of 4.73 and a beta of 0.66.

Analysts Set New Price Targets

A number of research firms recently weighed in on BAYRY. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Finally, Morgan Stanley raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Three equities research analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.